Use of a Fresenius Com.Tee Separator for Therapeutic Cytoreduction Erythrocytopheresis. (Pilot Study)
Využití separátoru FRESENIUS COM.TEC pro léčebné cytoredukční erytrocytaferézy. (Pilotní studie)
Autor popisuje využití kontinuálního separátoru COM.TEC firmy Fresenius při léčebných cytoredukčních erytrocytaferézách u 20 pacientů. Jsou uvedeny základní rozdíly oproti modelu Fresenius AS.TEC 204. Přístroj byl použit k redukci objemu erytrocytů u polycytemia vera, sekundárních polyglobuliích a hemochromatózy. Odebrané objemy erytrocytů byly v rozmezí 628-1472 ml. Byla sledována korelace cílového hematokritu nastaveného na přístroji se skutečným hematokritem změřeným po proceduře na hematologickém analyzátoru - průměrný rozdíl byl 2 %. Nebyly zaznamenány žádné nežádoucí účinky ani vedlejší příznaky.
Klíčová slova:
erytrocytaferézy, polyglobulie polycytema vera, hemochromatózy
Authors:
J. Pták
Authors‘ workplace:
Krevní centrum Fakultní nemocnice s poliklinikou, Ostrava
Published in:
Transfuze Hematol. dnes,, 2001, No. 4, p. 143-145.
Category:
Overview
The author describes the use of a continual COM.TEC Separator of Fresenius Co. in therapeutic cytoreduction erythrocytaphereses in 20 patients. He mentions the balic differences as compared with model Fresenius AS.TEC 204. The apparatus was used for reduction of the erythrocyte volume in polycythemia vera, secondary polyglobulie and haemochromatosis. The collected erythrocyte volumes esere within the range of 628-1472 ml. The author investigated the correlation of the target haematocrit set on the apparatus with the actual haematocrit assessed during the procedures on the haematological analyzer - the mean difference was 2 %. The author did not record any undesirable effects nor side-effects.
Key words:
eerytrocytapheresis, polyglobulie, polycytemia vera, haemochromatosis
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2001 Issue 4
- Neutralizing Antibodies Against Emicizumab – Detailed Analysis Based on a Case Study
- Position of aPCC in the Treatment of Hemophilia A Complicated by the Development of Inhibitors
- Sport and Physical Activity Benefit Hemophiliacs
- What FVIII Levels Are Ideal for Preventing Bleeding in Hemophilia A?
- Administration of aPCC as a Prevention of Bleeding After Major Cardiac Surgical Procedures
Most read in this issue
- Possibilitiesof Diagnosis and Differential Diagnosis of iron deficiency anaemia
- Development of hematopoietic stem cell transplantation in thetreatment of autoimmune diseases
- HLA-Cw Compatibility between Recipient and Donor in Molecular A, B, DR, DQ Compatible Non-related Bone Marrow Donors
- Use of a Fresenius Com.Tee Separator for Therapeutic Cytoreduction Erythrocytopheresis. (Pilot Study)